CDMOs offering Topical & Semi-Solid Manufacturing with Small Molecule in United States
8 matching organizations
Topical & Semi-Solid Manufacturing with Small Molecule in United States is a frequent shortlist pattern for sponsors evaluating CDMO partners with regional footprint. This page lists organizations that map to all three dimensions so you can move from broad taxonomy browsing to a geography-aware candidate set.
Profiles emphasize fit-first discovery: review scope, regulatory posture, and provenance on each listing rather than treating this page as a single ranked recommendation.
When you need additional filters (indications, claim status, or free-text search), continue to the main search experience and layer criteria on top of this starting point.
- Aenova Group
Aenova Group is a worldwide leading contract manufacturer for the pharmaceutical and healthcare industry, offering solid dosage, sterile technologies, semisolids, softgels, and packaging services across 15 manufacturing sites in Europe and North America.
- Bend Bioscience
U.S. pharmaceutical CDMO offering design, development, and manufacturing of oral solid and liquid dosage forms, from early formulation to commercial-scale production across three domestic locations.
- Catalent
Global CDMO providing end-to-end contract development and manufacturing for pharma, biotech, and consumer health. Delivers 60+ billion doses annually across small molecules, biologics, cell & gene therapies, and clinical supply.
- Halo Pharma
Halo Pharma provides end-to-end pharmaceutical development and manufacturing for small molecule therapeutics across solids, semi-solids, oral liquids, and sterile injectables, with two North American cGMP facilities and an accelerated 16–20 week tech transfer program.
- Medpharm
Specialized CDMO for topical, transdermal, and transepithelial drug products offering formulation development, analytical testing, process scale-up, and GMP manufacturing from early development through commercialization.
- Pharmaron
Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
- Syngene International
Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
- UPM Pharmaceuticals
Independent, family-owned CDMO specializing in oral solids, semi-solids, and controlled-substance manufacturing with 475,000 sq ft cGMP facility in Bristol, TN; over 80 products commercialized.
Markdown mirror: /explore/svc_topical_dosage/mod_small_molecule/us.md